![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2007, The Rockefeller University Press Article Huntingtin-interacting protein 14, a palmitoyl transferase required for exocytosis and targeting of CSP to synaptic vesicles 1Department of Molecular and Human Genetics, 2Howard Hughes Medical Institute, 3Department of Neuroscience, and 4Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030 Correspondence to Hugo J. Bellen: hbellen/at/bcm.tmc.edu Received October 9, 2007; Accepted November 14, 2007. This article has been cited by other articles in PMC.Abstract Posttranslational modification through palmitoylation regulates protein localization and function. In this study, we identify a role for the Drosophila melanogaster palmitoyl transferase Huntingtin-interacting protein 14 (HIP14) in neurotransmitter release. hip14 mutants show exocytic defects at low frequency stimulation and a nearly complete loss of synaptic transmission at higher temperature. Interestingly, two exocytic components known to be palmitoylated, cysteine string protein (CSP) and SNAP25, are severely mislocalized at hip14 mutant synapses. Complementary DNA rescue and localization experiments indicate that HIP14 is required solely in the nervous system and is essential for presynaptic function. Biochemical studies indicate that HIP14 palmitoylates CSP and that CSP is not palmitoylated in hip14 mutants. Furthermore, the hip14 exocytic defects can be suppressed by targeting CSP to synaptic vesicles using a chimeric protein approach. Our data indicate that HIP14 controls neurotransmitter release by regulating the trafficking of CSP to synapses. Introduction The precise localization of proteins to intracellular and plasma membrane domains is important for their proper function. Some intracellular proteins that play roles at the plasma membrane are modified by the addition of long-chain fatty acids that mediate protein targeting to the membrane (Dunphy and Linder, 1998). For example, the cotranslational attachment of myristic acid to an N-terminal glycine or the addition of fatty acids such as palmitate by thioester linkage to cysteine residues target proteins to specific subcellular compartments (Smotrys and Linder, 2004). Palmitate is a 16-carbon saturated fatty acid that is attached to proteins posttranslationally. This modification increases the hydrophobicity of the protein, thereby facilitating interactions with lipid bilayers. In neurons, at least 32 proteins have been shown to be palmitoylated. These include channels, cell adhesion molecules, and signaling proteins as well as the presynaptic proteins cysteine string protein (CSP), synaptotagmin I (Syt I), SNAP25, neuronal synaptobrevin (n-Syb), and Huntingtin (Htt; el-Husseini Ael and Bredt, 2002; Smotrys and Linder, 2004). Unlike myristoylation and isoprenylation, which are permanent modifications, the palmitoylation of proteins is regulated via a cycle of enzymes that add and remove palmitate (Smotrys and Linder, 2004). The reversibility of palmitoylation of neuronal proteins is likely to be an important regulatory event, as patients with mutations in palmitoyl-protein thioesterase 1 (PPT1), which removes palmitate, exhibit a debilitating and early onset neuronal degeneration leading to childhood death (Vesa et al., 1995). Recently, palmitoyl transferases (PATs) were discovered in Saccharomyces cerevisiae (Lobo et al., 2002; Roth et al., 2002). The defining feature of this family is the presence of a cysteine-rich domain (CRD) with an Asp-His-His-Cys (DHHC) motif, and it is required for PAT activity both in vitro and in vivo. Proteins with DHHC-CRD are conserved from yeast to mammals. Genetic and biochemical studies have identified substrates for several of the seven DHHC proteins in S. cerevisiae (Lobo et al., 2002; Roth et al., 2002), and proteomic analyses have expanded the repertoire of substrates for this family of enzymes significantly (Roth et al., 2006). Although the number of DHHC proteins in yeast is limited, flies contain 20 and mammals 23 DHHC proteins. Their tissue distribution and subcellular localization has been recently documented (Ohno et al., 2006). However, the in vivo role of these PATs in neurons has not been established. In this study, we report a novel genetic screen that allowed us to identify mutations that affect neurotransmitter release. This screen led to the identification of Drosophila melanogaster htt-interacting protein 14 (hip14), a protein that has not been implicated previously in synaptic transmission but has been shown to palmitoylate Htt in vertebrates (Yanai et al., 2006). The synaptic defects associated with the loss of hip14 show striking similarities with the loss of csp (Zinsmaier et al., 1994). In addition, CSP as well as SNAP25 are mislocalized in hip14 mutants, and palmitoylation of CSP is critical for its synaptic localization. In contrast, Syt I and postsynaptic density 95 (PSD-95)/Discs large (DLG), which can be modified by HIP14 in vitro (Huang et al., 2004), are localized properly in hip14 mutants. Based on biochemical data and functional rescue assays, our data not only point to the importance of palmitoylation in synaptic function but also reveal CSP as a novel and one of the main targets for HIP14 in vivo. Results Isolation of mutations in complementation group 3L1 To identify novel proteins that affect synaptic transmission, we performed a forward genetic screen on chromosome arm 3L using the ey-FLP system (Stowers and Schwarz, 1999; Newsome et al., 2000). In previous 2L, 2R, and 3R chromosome arm screens, we selected flies in the F1 generation with aberrant phototactic properties, and, of the progeny, we isolated mutants with abnormal electroretinograms (ERGs), thereby measuring the ability of photoreceptors (PRs) to activate postsynaptic cells (Verstreken et al., 2003, 2005; Mehta et al., 2005). Although neurotransmission mutants isolated from prior ey-FLP screens initially displayed reduced phototaxis in the F1 generation, many behaved normally in subsequent generations despite retaining their ERG defects (Fabian-Fine et al., 2003; Verstreken et al., 2003, 2005; Koh et al., 2004). Therefore, we modified the screening strategy and omitted the phototaxis assay. Thus, F1 flies were directly subjected to ERG recordings. Of the 49,017 screened F1 flies, 1,077 were crossed and rescreened in the F2 generation. 77 were eventually retained as mutants with abnormal ERGs. Complementation tests with mutants previously shown to affect synaptic transmission identified two new alleles of csp (Zinsmaier et al., 1994) and one new allele of SNAP (Ordway et al., 1994), demonstrating the specificity of the strategy. Upon further complementation analysis, we identified eight novel complementation groups with two or more alleles. Here, we describe 3L1, a complementation group with three alleles: 3L11, 3L12, and 3L13. As shown in Fig. 1 A
The ERG phenotype suggests that the PRs fail to properly transmit signals to postsynaptic neurons. This may be caused by (1) functional impairment of the neurotransmission machinery or (2) aberrant synapse formation. To test whether developmental defects are present at the light microscopy level, we first stained adult brains with the PR-specific antibody against chaoptin, mAb 24B10 (Fujita et al., 1982). The Drosophila compound eye consists of ~800 units, each comprised of eight PR cells that project into the lamina (R1–R6) or into two separate layers in the medulla (R7–R8; Fig. 1 B TEM of PR synapses in the lamina also allows us to assess some ultrastructural features, including the number of mitochondria, number of active zones, and size, number, and shape of glial cell invaginations or capitate projections. The capitate projections are thought to be centers of endocytosis in PR terminals (Fabian-Fine et al., 2003). Interestingly, as shown in Fig. 1 3L1 encodes Drosophila hip14 To identify the 3L1 gene, we mapped the lesions in the mutants using P-element meiotic recombination (Zhai et al., 2003). Rough mapping placed 3L1 in the 72A–C cytological interval and showed that the mutations fail to complement Df(3L)brm11 (Fig. 2 A
To determine whether the lethality and functional defects of the hip14 alleles can be rescued by CG6017, we generated a genomic rescue construct (Fig. 2 A HIP14 is conserved from yeast to humans over the entire length of the protein, sharing 50.8% identity with its human homologue and 31.3% identity with the yeast protein (Singaraja et al., 2002). Drosophila hip14 encodes a 71-kD protein with five ankyrin repeats, a DHHC-CRD typically found in PATs, and five transmembrane domains (TMDs), suggesting it is an integral membrane protein (Singaraja et al., 2002; Huang et al., 2004). Recently, a study has shown that the DHHC family of proteins functions as PATs, including the yeast homologue of hip14, Akr1p (Roth et al., 2002). In Drosophila, at least 20 genes share a common 50-residue zinc finger–like sequence, which contains the DHHC-CRD. No analyses of mutants of any of these proteins in nematodes, flies, or mice have been reported. HIP14 is localized pre- and postsynaptically Both mouse and human HIP14 are strongly expressed in the brain and heart, and immuno-EM studies suggest that HIP14 localizes to the Golgi as well as to diverse vesicular structures present in the soma, axon, and dendrites of neurons (Singaraja et al., 2002; Huang et al., 2004). To determine the expression pattern and subcellular localization of HIP14 in Drosophila, we generated N- and C-terminal GFP-tagged genomic constructs (Fig. 2 B In stage 13–15 embryos, GFP-HIP14 is observed in the central nervous system (CNS) neuropil (Fig. 3, A and B
NMJs develop normally in hip14 mutants Enhancer screens for genes involved in axon guidance and/or synaptogenesis at the Drosophila NMJ identified CG6017/hip14 (Kraut et al., 2001), suggesting that hip14 may play a role in growth cone guidance and/or synaptogenesis. However, our analysis of the hip14 PR projections failed to uncover any obvious morphological defects (Figs. 1, B and C
To determine whether there are ultrastructural defects, we performed TEM experiments of third instar NMJ boutons. We find that the mutants exhibit normal SV morphology and density, normal T-bar morphology, active zone length, and structure of the subsynaptic reticulum when compared with control animals (Fig. 4, C–F HIP14 is required for proper SV exocytosis To assess the synaptic defects in hip14 mutants, we used the third instar NMJ. To determine whether HIP14 regulates SV cycling at the synapse, we performed live imaging of vesicle cycling with FM 1-43 (Ramaswami et al., 1994). FM 1-43 is nonfluorescent in aqueous environments, but, when bound to membranes, its fluorescence quantum yield increases. Thus, newly endocytosed vesicles in the presence of FM 1-43 are fluorescently labeled by the dye, providing a quantitative measure of vesicle cycling. As shown in Fig. 5 A
To determine whether exocytosis is impaired at hip14 synapses, we stimulated mutant and control motor nerves at 0.2 Hz in 1 mM Ca2+ and recorded excitatory junctional potentials (EJPs) from the muscle. The EJP amplitudes in hip14 mutants during low frequency stimulation are ~33–40% of controls (wild type, 39.4 ± 2.4 mV; hip141, 13.2 ± 1.4 mV; hip142, 18.9 ± 0.6 mV) at 23°C (Fig. 5, C and D We also recorded miniature EJP amplitude and frequency. Both parameters are similar to controls (Fig. 5 G Because HIP14 is expressed both pre- and postsynaptically at the Drosophila NMJ (Fig. 3, D–H CSP and SNAP25 are not properly localized at hip14 NMJs Based on in vitro assays, mammalian HIP14 and the yeast homologue Akr1p are PATs (Babu et al., 2004; Huang et al., 2004) and are able to covalently attach palmitic acid to cysteine residues, thereby regulating the localization of various proteins. Although HIP14 is able to palmitoylate many neuronal proteins, including PSD-95, GAD43 (growth-associated protein 43), Syt I, SNAP25, and Htt in cell culture systems (Huang et al., 2004), the role and substrate specificity of HIP14 in neurons remain to be determined. Therefore, we examined the levels and protein distribution of presynaptic components that are known to be palmitoylated, including PSD-95/DLG, Syt I, n-Syb, SNAP25, and CSP (el-Husseini Ael and Bredt, 2002) in control and hip14 mutant boutons. We stained NMJs with anti-DLG, which strongly labels the postsynaptic membrane as well as the most peripheral component of the presynaptic membrane (Lahey et al., 1994). We did not observe any differences between control and mutant NMJs (Fig. 4 A
To test whether the reduction in CSP and SNAP25 at synapses can be attributed to a decrease in the expression or mislocalization of these proteins, we performed a Western blot using third instar larval brain tissue. Compared with controls, the amount of SNAP25 in mutant brain is not reduced on the Western blot (Fig. 6 F To determine whether the localization of CSP and SNAP25 is altered in hip14 mutants, we examined its expression in the larval VNC, where neuronal cell bodies reside. In hip14 mutants, CSP and SNAP25 are much more diffuse and more prominently localized in neuronal cell bodies when compared with controls, in which CSP and SNAP25 are more enriched in the neuropil (Fig. 6, G and H Palmitoylation of CSP requires HIP14 The previous data are consistent with the hypothesis that HIP14 palmitoylates CSP. CSP carries 11–13 palmitoylation sites (van de Goor and Kelly, 1996), and these posttranslational modifications are necessary for trafficking the protein from the ER in cultured cells (Greaves and Chamberlain, 2006). To assess the palmitoylation state of CSP in hip14 mutants, we compared wild-type CSP with CSP that is stripped of its palmitate residues through chemical treatment with hydroxylamine, a compound that has been shown to efficiently cleave posttranslational fatty acyl thioester groups of proteins (van de Goor and Kelly, 1996). As shown in Fig. 6 I Overexpressed CSP in hip14 mutants does not localize to NMJs and fails to rescue exocytic defects In addition to the severe reduction of CSP at hip14 synapses, our electrophysiological data show that hip14 mutants exhibit exocytic defects that are temperature sensitive (Fig. 5, C–F To explore whether trafficking of CSP to synapses is solely or predominantly dependent on palmitoylation by HIP14, we overexpressed CSP neuronally in hip14 mutants. We overexpressed wild-type UAS-CSP2, one of the three Drosophila isoforms expressed in neurons (Nie et al., 1999), which was previously shown to rescue csp-null mutants. In controls, CSP2 overexpression induced a fourfold up-regulation of CSP at the third instar larval NMJ relative to control animals (Fig. S4, A and B; available at http://www.jcb.org/cgi/content/full/jcb.200710061/DC1). However, in hip14 mutants, the levels of CSP at the boutons are not or are at most minimally up-regulated when compared with hip14 mutants that do not overexpress CSP (Fig. 7, A and C
To further determine whether the palmitoylation of CSP is necessary for targeting of the protein to the synapse, we examined whether SSP (Arnold et al., 2004) localizes to NMJ boutons. Similar to wild-type CSP in hip14 mutants, SSP does not or very poorly localizes to NMJ boutons when expressed in csp-null mutants (Fig. 7 D Chimeric CSP localizes to synapses and significantly rescues hip14 mutants Because CSP cannot be targeted to NMJ boutons in hip14 mutants, even when overexpressed, we generated a chimeric CSP in which full-length CSP2 is sandwiched between the N-terminal n-Syb sequence (111 bp) and the C-terminal n-Syb TMD (SybTMD; 234 bp) to forcibly target CSP to SVs at synapses. We expressed this chimeric CSP neuronally in csp-null mutants using elav-GAL4. Interestingly, the SybTMD-CSP2 protein is not only able to rescue the lethality of csp mutants but also the paralytic phenotype at 30°C even though it is expressed at lower levels than the wild-type CSP2 (Fig. S4, B–D). These data indicate that SybTMD-CSP2 is expressed and functional and further suggest that vesicle tethering of CSP is important for the function of CSP. To test whether SybTMD-CSP2 localizes to NMJ synapses independently of HIP14, we determined its localization in hip14 mutants. As shown in Fig. 7 E Because SNAP25 may be a substrate for the CSP chaperone complex, the mislocalization of SNAP25 in hip14 mutants may be caused by the mislocalization of CSP and not necessarily because of defective palmitoylation. However, our data suggest that this is not the case, as the SNAP25 levels are still reduced in hip14 mutants that express the chimeric CSP that localizes to NMJs (Fig. S5, available at http://www.jcb.org/cgi/content/full/jcb.200710061/DC1). Thus, HIP14-mediated palmitoylation of SNAP25 seems critical for its synaptic localization. If the exocytic defects in hip14 mutants largely stem from the mislocalization of CSP (Fig. 5, C–F Discussion Posttranslational modification by palmitate is critical for the proper localization and function of numerous proteins (Smotrys and Linder, 2004). The enzymes that mediate the addition of palmitate to proteins, PATs, were originally studied in S. cerevisiae (Roth et al., 2002) and are characterized by the presence of a CRD with an embedded DHHC motif that mediates the PAT activity of enzymes. Although DHHC-CRD proteins are conserved from yeast to mammals, no mutations in these proteins have been documented in any other model organism. Here, in an unbiased genetic screen to identify genes that affect synaptic transmission, we have identified mutants in hip14, a DHHC-CRD protein structurally conserved from yeast to man (Singaraja et al., 2002). Characterization of these mutants suggests that HIP14 plays an important role in synaptic function by mediating the palmitoylation and proper targeting of specific presynaptic proteins. The importance of proper protein palmitoylation in the nervous system has been suggested by several findings. For instance, patients with lesions PPT1, a depalmitoylating enzyme, suffer from an early onset neurodegeneration that leads to childhood death (Vesa et al., 1995). Loss of PPT1 in Drosophila has also been associated with a synaptic dysfunction based on genetic interaction experiments (Buff et al., 2007). In addition, the presence of expanded repeats in pathogenic Htt protein has been shown to render it less amenable to palmitoylation, enhancing the formation of inclusion bodies (Yanai et al., 2006). However, the consequences on synaptic transmission of aberrant or absent palmitoylation in neurons have not been investigated in vivo. Mammalian HIP14 is expressed ubiquitously but is most prominently present in the brain (Singaraja et al., 2002). Here, we find that GFP-HIP14 is expressed throughout the nervous system during development and in third instar larvae but is strongly enriched in the neuropil. Furthermore, the presynaptic expression of HIP14 rescues the lethality and phenotype of hip14 mutants, suggesting that it plays a critical role in presynaptic function. This is further substantiated by the observations that the miniature EJP amplitude and frequency are similar to wild type and that GluRIII localization is normal. All DHHC proteins, with the exception of yeast Ynl155W, are integral membrane proteins with four or more TMDs (Mitchell et al., 2006). The DHHC-CRD motif is typically located between two TMDs and is predicted to face the cytosol (Politis et al., 2005). Human HIP14 was shown to be localized at the Golgi and in cytoplasmic vesicles marked with SNAP25 in cultured neurons or transfected cells (Huang et al., 2004). We find that HIP14 mostly colocalizes with CSP and n-Syb at the synapse. Because HIP14 relocalizes to the presynaptic membrane upon SV depletion and harbors several TMDs, these data are consistent with HIP14 being an SV and presynaptic membrane-associated protein. There are 20 DHHC proteins in Drosophila, raising issues about the protein specificity of each DHHC protein family member. Because there are numerous DHHC proteins, it is likely that each protein has one or a few specific target substrates. This may be unsurprising, as palmitoylation is a highly regulated event, and DHHC proteins are likely to be targeted to very specific cellular compartments, where they act locally on few targets. A previous mammalian study in culture systems shows that HIP14 is a PAT and suggests that candidate targets include PSD-95/DLG, Htt, Syt I, SNAP25, GAD43, and GAD65 (Huang et al., 2004). In addition, RNAi knockdown analyses in neurons have provided evidence that HIP14 modulates palmitoylation-dependent protein trafficking of PSD-95, GAD65, and Htt (Huang et al., 2004; Yanai et al., 2006). However, the role of HIP14 in neuronal activity and synaptic transmission had not been documented. We find that HIP14 directly regulates the localization of two important presynaptic proteins: CSP and SNAP25. However, we did not observe any difference in the localization of DLG, n-Syb, and Syt I. We focused on CSP for several reasons. First, the loss of SNAP25 in Drosophila causes very mild exocytic defects. It has been proposed that this is the result of the redundant function of SNAP24 (Vilinsky et al., 2002). Second, the electrophysiological phenotype associated with the loss of HIP14 strongly resembles the unique temperature-sensitive phenotype associated with the loss of CSP (Zinsmaier et al., 1994), indicating that CSP is one of the main targets of HIP14. Third, it was previously shown that CSP is heavily palmitoylated and that this posttranslational modification is required in vivo (van de Goor and Kelly, 1996; Arnold et al., 2004). Collectively, these data suggest that much of the phenotype we observe in hip14 mutants is caused by the loss of CSP function. However, note that although the functional defects in hip14 strongly resemble those seen in csp mutants, the developmental defects, including the reduction in bouton number in csp mutants (Bronk et al., 2005), are not observed in hip14, indicating that palmitoylation- independent roles for CSP in neurons also exist. The SV-associated protein CSP is critical for regulating neurotransmitter release and has been shown to prevent neuronal degeneration (Fernandez-Chacon et al., 2004; Zinsmaier et al., 1994). CSP binds the chaperone heat-shock cognate protein Hsc70 and regulates its ATP activity, and this cooperativity is required for regulated neurotransmitter release at synaptic terminals (Bronk et al., 2001). These data have led to the proposal that CSP is a chaperone that renatures nerve terminal proteins that misfold during the continuous operation of the SV cycle, a view which is supported by genetic studies in mice and Drosophila (Zinsmaier et al., 1994; Fernandez-Chacon et al., 2004). Binding experiments suggest that the protective effect may be mediated by CSP interacting with candidate substrates such as the SV protein n-Syb and the plasma membrane protein Syntaxin (Zinsmaier and Bronk, 2001). CSP possesses a cysteine-rich region containing a high density of cysteine residues (14 in a span of 24 amino acids in mammals). Most of these cysteines are palmitoylated, a process proposed to be necessary for the secretion of CSP from the ER (Chamberlain and Burgoyne, 1998; Greaves and Chamberlain, 2006). Our data indicate that HIP14 is the PAT for CSP and that in the absence of HIP14, CSP is retained in the cell body. Furthermore, SSP is also retained in the cell body when overexpressed in neurons (Fig. S3 B). Thus, these data are consistent with a role for HIP14 in regulating the proper synaptic targeting of CSP. The observation that a chimeric CSP rescues much of the exocytic defects associated with the loss of hip14 mutants provides compelling evidence that a main function of HIP14 is the palmitoylation of CSP. This palmitoylation is most likely not only required in the cell body for proper targeting of CSP to the synaptic terminals; indeed, synaptic HIP14 may also play a role in a palmitoylation cycle occurring at synapses. The loss of CSP and the expression of expanded Htt protein have both been shown to be associated with synaptic defects in exocytosis and neuronal degeneration (Zinsmaier et al., 1994; Fernandez-Chacon et al., 2004; Romero et al., 2007). Interestingly, our preliminary analyses suggest that wild-type human Htt and 128Q-expanded human Htt proteins are both mislocalized in flies lacking HIP14 (unpublished data). Thus, Htt also appears to be palmitoylated by HIP14 in Drosophila, which is similar to what has been observed in mice (Huang et al., 2004). Although we have not yet explored the effect of hip14 mutations on neuronal degeneration, it will be interesting to explore the relationship between HIP14, CSP, and Htt in the processes of synaptic transmission and neuronal degeneration in more detail. Materials and methods Genetics and molecular biology Control animals are isogenized (y w ey-FLP GMR-lacZ; FRT80B) unless otherwise indicated. 3L11, 3L12, and 3L13 mutants (y w ey-FLP GMR-lacZ;3L1x FRT80B/TM6B, Tb) were isolated from an ey-FLP ethane methyl sulfonate screen as described previously (Verstreken et al., 2003) with modifications. cspx1 mutants and UAS-ssp (w;; P{w+ UAS-csp-11c/s}, cspu1) flies were provided by K. Zinsmaier (University of Arizona, Tucson, AZ). P-element stocks and deficiencies were obtained from the Bloomington Drosophila Stock Center (Bellen et al., 2004; Parks et al., 2004), and 3L1 mapping was performed as described previously (Zhai et al., 2003). We made a genomic rescue construct by PCR amplifying the 6.5-kb hip14 region from bacterial artificial chromosome clone AC093499. The fragment was cloned into the SalI restriction site of pP{CaSpeR-4} and sequenced. A cDNA construct was made by PCR amplifying hip14 from expressed sequence tag clone LD10758. The fragment was cloned into NotI and XbaI sites of pP{UAST} and sequenced. To generate genomic GFP-tagged constructs, we first integrated an NheI site just before the ATG start codon (NtermGFP-HIP14) or after the hip14 stop codon (CtermGFP-HIP14) by site-directed mutagenesis (Stratagene). PCR-amplified EGFP sequence was cloned into the NheI site. We generated chimeric n-SybTMD-CSP constructs by PCR amplifying 111-bp N-terminal and 234-bp C-terminal n-syb sequences from pP{UAST}-syb-GFP and the full-length CSP2 from pP{UAST}-csp2 (provided by K. Zinsmaier). In the next round of PCR, we fused them to generate N-terminal-Syb-csp2-C-terminal-Syb chimeric (SybTMD-csp2). After sequencing, SybTMD-csp2 was cloned into pP{UAST} at NotI and XbaI. P{w+ UAS-SybTMD-csp2} and P{w+ UAS-csp2} were expressed using elav-GAL4. For analyses of CSP localization and physiology of third instar larvae, we generated elav-GAL4/+; P{w+UAS-SybTMD-csp2} hip142 FRT80B/Df(3L)brm11 and elav-GAL4/+; hip142 FRT80B P{w+ UAS-csp2}/Df(3L)brm11. Immunohistochemistry and Western blotting For staining third instar larvae and adults, brains were dissected in modified HL3 solution (110 mM NaCl, 5 mM KCl, 10 mM NaHCO3, 5 mM Hepes, 30 mM sucrose, 5 mM trehalose, and 10 mM MgCl2, pH 7.2) and fixed in 4% formaldehyde for 20 min. Tissue was washed with PBS and permeabilized with 0.4% Triton X-100. For shibirets experiments, third instar larvae were dissected in modified HL3 solution, incubated at 32°C for 5 min, and stimulated in prewarmed modified HL3 solution with 90 mM KCl and 1.5 mM Ca2+ for 5 min. After stimulation, the samples were fixed in 4% formaldehyde for 20 min. Labeling was performed according to standard protocols. Samples were mounted in Vectashield (Vector Laboratories) and were imaged using a confocal microscope (LSM 510; Carl Zeiss, Inc.) with the accompanying LSM5 software (Carl Zeiss, Inc.) at RT. Identical settings were used for control and experimental samples. In Fig. 1 (B and C) Antibodies that recognize the following proteins were used at the indicated dilutions for immunohistochemistry/Western blotting: Syt I at 1:5,000/1:10,000 (Littleton et al., 1993), n-Syb at 1:200/1:1,000, CSP at 1:100/1:1,000 (Zinsmaier et al., 1994), and SNAP25 at 1:200/1:1,000 (Vilinsky et al., 2002). The following antibodies were used only for immunohistochemistry: DLG (mouse mAb 4F3) at 1:50 (Parnas et al., 2001), DLG (rabbit polyclonal; provided by K. Choi, Baylor College of Medicine, Houston, TX) at 1:500, HRP (rabbit; Jackson ImmunoResearch Laboratories) at 1:200, mouse mAb 24B10 (Futsch) at 1:50, mouse mAb nc82 (Bruchpilot) at 1:100 (Kittel et al., 2006), Fasciclin II (mouse mAb 1D4) at 1:10 (Zito et al., 1997), GluRIII rabbit polyclonal (provided by A. DiAntonio, Washington University, St. Louis, MI) at 1:5,000 (Marrus et al., 2004), and GFP (rabbit; Invitrogen) at 1:500. AlexaFluor488- (Invitrogen) and Cy3 (Jackson ImmunoResearch Laboratories)-conjugated secondary antibodies were used at 1:250. HRP-conjugated antibodies (Jackson ImmunoResearch Laboratories) were used at 1:2,500 for Western blotting. Western blots were developed with ECL reagents (PerkinElmer). Quantification For synaptic protein quantification, anti-DLG (rabbit or mouse) was used to outline type I boutons (Lahey et al., 1994). Boutons were scanned with z steps of 0.5 μm. Using Amira software, the DLG-stained type I boutons in each confocal slice were highlighted, and the mean pixel intensity of all slices of the highlighted boutons of each NMJ were computed. Background fluorescence in muscle areas adjacent to the boutons was quantified similarly, and the background was subtracted from the bouton values to yield the mean intensity of labeling in the boutons. The mean value from at least three mutant NMJs was then expressed as a percentage of the corresponding control value. ERG assay ERGs were performed as described previously (Fabian-Fine et al., 2003; Verstreken et al., 2003); flies were immobilized with one eye and part of the thorax in a small drop of Elmer's school glue on a microscope slide. For the 3L screen, ~50–100 male F1 flies were subjected to two ERG recordings. Flies with mutant ERGs were liberated and subsequently mated. Electrophysiology and FM 1-43 dye uptake For FM 1-43 dye uptake experiments and electrophysiological recordings, third instar larvae were dissected in modified HL3 without Ca2+, and motor neurons were cut. Larvae were stimulated in modified HL3 solution at ambient temperature with 4 μM FM 1-43, 90 mM KCl, and 1.5 mM Ca2+ for 1 min and were washed with modified HL3 solution. Images were captured using a microscope (Axioskop; Carl Zeiss, Inc.) with Axiovision 4.2 software (Carl Zeiss, Inc.), a 40× 0.75-W water immersion lens (Carl Zeiss, Inc.), and a camera (MRm; Carl Zeiss, Inc.) at RT. The intensity of FM 1-43 was analyzed and quantified as described previously (Verstreken et al., 2007). EJPs and miniature EJPs recorded the membrane potential of muscle 6 using sharp 90–110 MΩ electrodes as described previously (Koh et al., 2004). The temperature of the preparations was controlled as described previously (Koh et al., 2004). The data were analyzed by Clampfit (MDS Analytical Technologies) for EJPs and by Mini Analysis Program 6.0.3 (Synaptosoft) for miniature EJPs. TEM TEM of PRs and NMJ boutons was performed as described previously (Verstreken et al., 2003). Images were captured using a transmission electron microscope (model 1010; JEOL) with a camera (US1000; Gatan) and digital micrograph. For the PRs and NMJ boutons, 3,000× and 8,000× magnifications were used, respectively. For statistical analyses, cross sections of 10 cartridges or boutons from three different animals were measured using ImageJ (National Institutes of Health). Depalmitoylation assay Third instar larvae from control and mutant animals were homogenized in lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 5 mM EDTA, pH 7.4, and 2% Triton X-100). After centrifugation at 16,000 g, the proteins in the soluble fraction were precipitated by the chloroform-methanol precipitation method. The pellet was resuspended in SDS lysis buffer (50 mM Tris-Cl, 5 mM EDTA, and 4% SDS) and treated with 150 mM NaCl and 2% Triton X-100 with or without 1 M hydroxylamine, pH 7.0, at ambient for 2 h. After hydroxylamine treatment, samples were boiled in SDS sample buffer and subjected to SDS-PAGE. Online supplemental material Fig. S1 shows that control and 3L1 mutant PR terminals in the lamina are correctly organized. Fig. S2 shows that CtermGFP-HIP14 is enriched in the CNS and synaptic terminal similar to NtermGFP-HIP14 and that GFP-HIP14 is colocalized with the SV marker n-Syb at NMJs. Fig. S3 shows the mislocalization of SNAP25 in hip14 mutants (A) and SSP in csp mutants (B) at the VNC. Fig. S4 shows the expression level of CSP2 and SybTMD-CSP2. Fig. S5 shows that SNAP25 levels are not restored in hip14 mutant larvae that overexpress SybTMD-CSP2, indicating that the mislocalization of SNAP25 in hip14 mutants is not caused by CSP reduction at the synaptic terminal. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200710061/DC1. [Supplemental Material Index]
Acknowledgments We are grateful to the Bloomington Stock Center, the Developmental Studies Hybridoma Bank, K. Zinsmaier, K. Choi, A. DiAntonio, and D.L. Deitcher for reagents. We thank N. Giagtzoglou, C-K. Yao, Y.Q. Lin, and other members of the Bellen laboratory for comments. We thank Yuchun He for injections to generate the transgenic lines. Confocal microscopy was supported by the Mental Retardation and Developmental Disabilities Research Center at Baylor College of Medicine. P. Verstreken was supported by an R.L. Kirchstein National Research Service award, a Marie Curie Excellence Grant (MEXT-CT-2006-042267), the Research Fund Katholieke Universiteit Leuven, and Vlaams Instituut voor Biotechnologie. C.V. Ly was supported by a National Research Service Award, and H.J. Bellen is a Howard Hughes Medical Institute Investigator. Notes P. Verstreken's present address is Vlaams Instituut voor Biotechnologie, Department of Molecular and Developmental Genetics, Katholieke Universiteit Leuven, Center for Human Genetics, 3000 Leuven, Belgium. Abbreviations used in this paper: CNS, central nervous system; CRD, cysteine-rich domain; CSP, cysteine string protein; DLG, Discs large; EJP, excitatory junctional potential; ERG, electroretinogram; HIP14, Htt-interacting protein 14; Htt, Huntingtin; NMJ, neuromuscular junction; n-Syb, neuronal synaptobrevin; PAT, palmitoyl transferase; PPT1, palmitoyl-protein thioesterase 1; PR, photoreceptor; PSD-95, postsynaptic density 95; SSP, serine string protein; SV, synaptic vesicle; Syt I, synaptotagmin I; TEM, transmission EM; TMD, transmembrane domain; VNC, ventral nerve cord. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Biochim Biophys Acta. 1998 Dec 8; 1436(1-2):245-61.
[Biochim Biophys Acta. 1998]Annu Rev Biochem. 2004; 73():559-87.
[Annu Rev Biochem. 2004]Nat Rev Neurosci. 2002 Oct; 3(10):791-802.
[Nat Rev Neurosci. 2002]Annu Rev Biochem. 2004; 73():559-87.
[Annu Rev Biochem. 2004]Nature. 1995 Aug 17; 376(6541):584-7.
[Nature. 1995]J Biol Chem. 2002 Oct 25; 277(43):41268-73.
[J Biol Chem. 2002]J Cell Biol. 2002 Oct 14; 159(1):23-8.
[J Cell Biol. 2002]Cell. 2006 Jun 2; 125(5):1003-13.
[Cell. 2006]Biochim Biophys Acta. 2006 Apr; 1761(4):474-83.
[Biochim Biophys Acta. 2006]Nat Neurosci. 2006 Jun; 9(6):824-31.
[Nat Neurosci. 2006]Science. 1994 Feb 18; 263(5149):977-80.
[Science. 1994]Neuron. 2004 Dec 16; 44(6):977-86.
[Neuron. 2004]Genetics. 1999 Aug; 152(4):1631-9.
[Genetics. 1999]Development. 2000 Feb; 127(4):851-60.
[Development. 2000]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Neuron. 2005 Aug 4; 47(3):365-78.
[Neuron. 2005]Neuron. 2005 Apr 21; 46(2):219-32.
[Neuron. 2005]Proc Natl Acad Sci U S A. 1982 Dec; 79(24):7929-33.
[Proc Natl Acad Sci U S A. 1982]J Neurosci. 2003 Nov 19; 23(33):10732-44.
[J Neurosci. 2003]Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10860-5.
[Proc Natl Acad Sci U S A. 2003]Hum Mol Genet. 2002 Nov 1; 11(23):2815-28.
[Hum Mol Genet. 2002]Hum Mol Genet. 2002 Nov 1; 11(23):2815-28.
[Hum Mol Genet. 2002]Neuron. 2004 Dec 16; 44(6):977-86.
[Neuron. 2004]J Cell Biol. 2002 Oct 14; 159(1):23-8.
[J Cell Biol. 2002]Hum Mol Genet. 2002 Nov 1; 11(23):2815-28.
[Hum Mol Genet. 2002]Neuron. 2004 Dec 16; 44(6):977-86.
[Neuron. 2004]Nat Cell Biol. 2005 Jun; 7(6):612-8.
[Nat Cell Biol. 2005]Curr Biol. 2001 Mar 20; 11(6):417-30.
[Curr Biol. 2001]Neuron. 1994 Oct; 13(4):823-35.
[Neuron. 1994]Proc Natl Acad Sci U S A. 1982 Apr; 79(8):2700-4.
[Proc Natl Acad Sci U S A. 1982]Science. 2006 May 19; 312(5776):1051-4.
[Science. 2006]Neuron. 1998 Dec; 21(6):1465-75.
[Neuron. 1998]EMBO J. 2002 Apr 2; 21(7):1661-72.
[EMBO J. 2002]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 1994 Aug; 13(2):363-75.
[Neuron. 1994]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Science. 1994 Feb 18; 263(5149):977-80.
[Science. 1994]Neuron. 1997 Dec; 19(6):1237-48.
[Neuron. 1997]J Biol Chem. 2004 Jun 25; 279(26):27138-47.
[J Biol Chem. 2004]Neuron. 2004 Dec 16; 44(6):977-86.
[Neuron. 2004]Nat Rev Neurosci. 2002 Oct; 3(10):791-802.
[Nat Rev Neurosci. 2002]Neuron. 1994 Oct; 13(4):823-35.
[Neuron. 1994]FEBS Lett. 1996 Feb 19; 380(3):251-6.
[FEBS Lett. 1996]Mol Biol Cell. 2006 Nov; 17(11):4748-59.
[Mol Biol Cell. 2006]J Exp Biol. 2004 Mar; 207(Pt 8):1323-34.
[J Exp Biol. 2004]Biochem J. 1998 Oct 15; 335 ( Pt 2)():205-9.
[Biochem J. 1998]Science. 1994 Feb 18; 263(5149):977-80.
[Science. 1994]Genetics. 2002 Sep; 162(1):259-71.
[Genetics. 2002]J Neurosci. 1999 Dec 1; 19(23):10270-9.
[J Neurosci. 1999]J Exp Biol. 2004 Mar; 207(Pt 8):1323-34.
[J Exp Biol. 2004]Annu Rev Biochem. 2004; 73():559-87.
[Annu Rev Biochem. 2004]J Cell Biol. 2002 Oct 14; 159(1):23-8.
[J Cell Biol. 2002]Hum Mol Genet. 2002 Nov 1; 11(23):2815-28.
[Hum Mol Genet. 2002]Nature. 1995 Aug 17; 376(6541):584-7.
[Nature. 1995]Genetics. 2007 May; 176(1):209-20.
[Genetics. 2007]Nat Neurosci. 2006 Jun; 9(6):824-31.
[Nat Neurosci. 2006]Hum Mol Genet. 2002 Nov 1; 11(23):2815-28.
[Hum Mol Genet. 2002]J Lipid Res. 2006 Jun; 47(6):1118-27.
[J Lipid Res. 2006]J Biol Chem. 2005 Mar 18; 280(11):10156-63.
[J Biol Chem. 2005]Neuron. 2004 Dec 16; 44(6):977-86.
[Neuron. 2004]Neuron. 2004 Dec 16; 44(6):977-86.
[Neuron. 2004]Nat Neurosci. 2006 Jun; 9(6):824-31.
[Nat Neurosci. 2006]Genetics. 2002 Sep; 162(1):259-71.
[Genetics. 2002]Science. 1994 Feb 18; 263(5149):977-80.
[Science. 1994]FEBS Lett. 1996 Feb 19; 380(3):251-6.
[FEBS Lett. 1996]J Exp Biol. 2004 Mar; 207(Pt 8):1323-34.
[J Exp Biol. 2004]J Neurosci. 2005 Mar 2; 25(9):2204-14.
[J Neurosci. 2005]Neuron. 2004 Apr 22; 42(2):237-51.
[Neuron. 2004]Science. 1994 Feb 18; 263(5149):977-80.
[Science. 1994]Neuron. 2001 May; 30(2):475-88.
[Neuron. 2001]Biochem Pharmacol. 2001 Jul 1; 62(1):1-11.
[Biochem Pharmacol. 2001]Biochem J. 1998 Oct 15; 335 ( Pt 2)():205-9.
[Biochem J. 1998]Mol Biol Cell. 2006 Nov; 17(11):4748-59.
[Mol Biol Cell. 2006]Science. 1994 Feb 18; 263(5149):977-80.
[Science. 1994]Neuron. 2004 Apr 22; 42(2):237-51.
[Neuron. 2004]Neuron. 2004 Dec 16; 44(6):977-86.
[Neuron. 2004]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Genetics. 2004 Jun; 167(2):761-81.
[Genetics. 2004]Nat Genet. 2004 Mar; 36(3):288-92.
[Nat Genet. 2004]Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10860-5.
[Proc Natl Acad Sci U S A. 2003]Cell. 1993 Sep 24; 74(6):1125-34.
[Cell. 1993]Science. 1994 Feb 18; 263(5149):977-80.
[Science. 1994]Genetics. 2002 Sep; 162(1):259-71.
[Genetics. 2002]Neuron. 2001 Nov 8; 32(3):415-24.
[Neuron. 2001]Science. 2006 May 19; 312(5776):1051-4.
[Science. 2006]Neuron. 1994 Oct; 13(4):823-35.
[Neuron. 1994]J Neurosci. 2003 Nov 19; 23(33):10732-44.
[J Neurosci. 2003]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]